| Texto completo | |
| Autor(es): |
Reis, Sabrina Karen
;
Socca, Eduardo Augusto Rabelo
;
de Souza, Bianca Ribeiro
;
Genaro, Sandra Cristina
;
Duran, Nelson
;
Favaro, Wagner Jose
Número total de Autores: 6
|
| Tipo de documento: | Artigo Científico |
| Fonte: | TISSUE & CELL; v. 87, p. 12-pg., 2024-01-20. |
| Resumo | |
The current study investigated the potential effects of probiotic supplementation on colorectal carcinogenesis chemically induced with 1,2-dimethylhydrazine (DMH) and treated with 5-fluorouracil (5FU)-based chemotherapy in mice. Animals were randomly allocated in five different groups: Control: which not receive any treatment throughout the experimental course; Colitis model group (DMH): treated with DMH; DMH+ 5FU: animals received I.P. (intraperitoneal) dose of chemotherapy on a weekly basis; DMH+PROB: animals received daily administrations (via gavage) of probiotics (Lactobacillus: acidophilus and paracasei, Bifidobacterium lactis and bifidum); and DMH+ PROB+ 5FU: animals received the same treatment as the previous groups. After ten-week treatment, mice's large intestine was collected and subjected to colon length, histopathological, periodic acidschiff (PAS) staining and immunohistochemistry (TLR2, MyD88, NF-kappa B, IL-6, TLR4, TRIF, IRF-3, IFN-gamma, Ki-67, KRAS, p53, IL-10, and TGF-beta) analyzes. Variance (ANOVA) and Kruskal-Wallis tests were used for statistical analysis, at significance level p 0.05. Probiotics' supplementation has increased the production of Ki-67 cellproliferation marker, reduced body weight, and colon shortening, as well as modulated the chronic inflammatory process in colorectal carcinogenesis by inhibiting NF-kappa B expression and mitigating mucin depletion. Thus, these findings lay a basis for guide future studies focused on probiotics' action mechanisms in tumor microenvironment which might have implications in clinical practice. (AU) | |
| Processo FAPESP: | 20/03419-6 - Efeitos terapêuticos e toxicológicos da imunoterapia com OncoTherad (MRB-CFI-1) em pacientes com câncer de bexiga não-músculo invasivo recidivado não responsivo à terapia com Bacillus Calmette-Guérin (BCG) |
| Beneficiário: | Wagner José Fávaro |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |